N@N

Sarah James Reiterated (ACAD) at Buy and Held Target at $42 on, Aug 22nd, 2023

Sarah James of Cantor Fitzgerald, Reiterated "ACADIA Pharmaceuticals Inc." (ACAD) at Buy and Held Target at $42 on, Aug 22nd, 2023.

Sarah has made no other calls on ACAD in the last 4 months.

There are 10 other peers that have a rating on ACAD. Out of the 10 peers that are also analyzing ACAD, 6 agree with Sarah's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Julio Romero of "JP Morgan" Maintained at Hold with Increased Target to $29 on, Monday, August 7th, 2023
• Jay Olson of "Oppenheimer" Reiterated at Hold and Held Target at $25 on, Thursday, August 3rd, 2023
• Jeffrey Hung of "Morgan Stanley" Reiterated at Hold and Held Target at $30 on, Thursday, August 3rd, 2023
• Neena Bitritto-Garg of "Citigroup" Maintained at Hold with Increased Target to $27 on, Friday, July 14th, 2023
• Uy Ear of "Mizuho" Reiterated at Hold and Held Target at $20 on, Wednesday, June 14th, 2023
• Tazeen Ahmad of "B of A Securities" Maintained at Hold with Increased Target to $26 on, Monday, May 22nd, 2023

These are the ratings of the 4 analyists that currently disagree with Sarah

---

• Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $38 on, Thursday, August 3rd, 2023
• Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $33 on, Thursday, August 3rd, 2023
• Gregory Renza of "RBC Capital" Maintained at Buy with Increased Target to $33 on, Friday, July 14th, 2023
• Jason Butler of "JMP Securities" Maintained at Buy with Increased Target to $39 on, Friday, July 14th, 2023

Contributing Sources

---